FindMyKOL
Clinical trialNCT07116746Active, not recruitingPhase 2Interventional

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

SponsorArthrosi TherapeuticsEnrollment15GoutGout ChronicGouty ArthritisHyperuricemiaRefractory GoutTophaceous Gout+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Arthrosi Investigative Site (105)

    Margate, Florida, United States

  • Arthrosi Investigative Site (102)

    Miami, Florida, United States

  • Arthrosi Investigative Site (109)

    Tampa, Florida, United States

  • Arthrosi Investigative Site (106)

    Jackson, Mississippi, United States

  • Arthrosi Investigative Site (108)

    Charlotte, North Carolina, United States

  • Arthrosi Investigative Site (103)

    Duncansville, Pennsylvania, United States

  • Arthrosi Investigative Site (104)

    West Lake Hills, Texas, United States

  • Arthrosi Investigative Site (107)

    Bellevue, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AR882 75 mgXOI High DoseXOI Low Dose
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
3 Dec 2025
Primary completion
30 Nov 2026
Completion
28 Feb 2027
Last update posted
15 May 2026
Registered enrollment
15
Registry id
NCT07116746
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.